Fluvoxamine, an antidepressant, should not be used against Covid in the current state of knowledge, the French health authorities estimated on Tuesday, judging the few works going in the direction of a benefit insufficient. “The data available to date, due to their methodological limitations, do not support a clinical benefit of fluvoxamine as a curative treatment for Covid-19 disease”, summarized in a press release the National Security Agency of medicine (ANSM).
Fluvoxamine, widely used as an antidepressant, is one of the few already existing drugs that has given interesting results against severe forms of Covid. Unlike now discredited tracks like chloroquine or ivermectin, some credible studies suggest that it can reduce the risk of complications. Such a prospect is particularly interesting because the cost of such a treatment, which has long been in circulation, would be much lower than that of anti-Covid drugs developed specifically for this purpose, such as Pfizer’s Paxlovid pill.
